 The FDA signaled in briefing documents released that it may approve Bluebird bio Incs NASDAQ: BLUE beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act PDUFA goal dates for beti-cel. 